Publication Name	World Journal of Diabetes
Manuscript ID	3940
Country	United States

Received	2013-06-03 11:13
Peer-Review Started	2013-06-03 15:17
To Make the First Decision
Return for Revision
Revised
Second Decision	2013-06-18 11:01
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief	2013-06-19 00:45
Articles in Press
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2013-08-15 11:13
Publish the Manuscript Online	2013-12-20 16:49

ISSN	1948-9358 (online)
Open Access
Copyright
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Nutrition & Dietetics
Manuscript Type	Topic Highlights
Article Title	Vascular endothelial growth factor trap-eye (Aflibercept) for the management of diabetic macular edema
Manuscript Source	Invited Manuscript
All Author List	Ahmadreza Moradi, Yasir Jamal Sepah, Mohammad Ali Sadiq, Humzah Nasir, Salima Kherani, Raafay Sophie, Diana V Do and Quan Dong Nguyen
Funding Agency and Grant Number
Corresponding Author	Quan Dong Nguyen, MD, MSc, Stanley M Truhlsen Eye Institute, University of Nebraska Medical Center, Emile St, Omaha, NE 68198, United States. quan.nguyen@unmc.edu
Key Words	Diabetic macular edema; Diabetic retinopathy; Anti-vascular endothelial growth factor agents; Vascular endothelial growth factor trap-eye; Aflibercept; EYLEA
Core Tip	Several different agents have been approved recently for the treatment of diabetic macular edema (DME). The index article outlines the role of aflibercept, an anti-vascular endothelial growth factor (VEGF) agent, as a potential therapeutic option. Results from DME trials with aflibercept have been favorable and comparable to other anti-VEGF agents. Because of its longer half-life, aflibercept may also decrease the frequency of injections for DME patients. These results could be attributed to the stronger and prolonged binding of aflibercept to the VEGF-A receptor compared to other available antagonists. A better understanding of the effect of this drug in DME is expected once the phase 3 trial results are available.
Publish Date	2013-12-20 16:49
Citation	Moradi A, Sepah YJ, Sadiq MA, Nasir H, Kherani S, Sophie R, Do DV, Nguyen QD. Vascular endothelial growth factor trap-eye (Aflibercept) for the management of diabetic macular edema. World J Diabetes 2013; 4(6): 303-309 Available from: URL: http://www.wjgnet.com/1948-9358/full/v4/i6/303.htm DOI: http://dx.doi.org/10.4239/wjd.v4.i6.303
URL	http://www.wjgnet.com/1948-9358/full/v4/i6/303.htm
DOI	http://dx.doi.org/10.4239/wjd.v4.i6.303

Full Article (PDF)	WJD-4-303.pdf
Full Article (Word)	WJD-4-303.doc
Manuscript File	3940-Review.docx
Answering Reviewers	3940-Answering reviewers.pdf
Copyright License Agreement	3940-Copyright assignment.pdf
Peer-review Report	3940-Peer review(s).pdf
Scientific Editor Work List	3940-Scientific editor work list.doc